Company intelligence / Profile preview
Inovio Pharmaceuticals, Inc.
Plymouth Meeting, Pennsylvania, United Statesinovio.com ↗
- Ownership
- Public · INO
- Employees
- ~262
- Development stage
- Other
01
Overview
Preparing to submit BLA for INO-3107 for Recurrent Respiratory Papillomatosis (RRP). Reported Q3 2024 financials showing revenue of $0.1 million and a net loss of $39.4 million. Recently priced a $30 million public offering in December 2024.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- DNA medicinesDNA plasmidsDNA vaccinesDNA immunotherapies
- Industry
- Biotech
02
Drug pipeline
61 assets60 more assets in the full pipeline.
03
Partnerships
Partnerships with several companies and government bodies for infectious disease therapeutics development
04
Financials
- Market cap
- $100.2M
- Total revenue
- $65.3K
- Enterprise value
- $71.5M
Beyond the preview
Go deeper on Inovio Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inovio Pharmaceuticals, Inc..